Rachel Pearce
Overview
Explore the profile of Rachel Pearce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fox T, Massey V, Lever C, Pearce R, Laurence A, Grace S, et al.
J Clin Immunol
. 2025 Jan;
45(1):64.
PMID: 39760904
Allogeneic haematopoietic stem cell transplantation (alloHSCT) is safe and effective for adolescents and adults with inborn errors of immunity (IEI) with severe disease manifestations of their disease. The haematopoietic cell...
2.
Elfeky R, Builes N, Pearce R, Kania S, Nademi Z, Lucchini G, et al.
Blood Adv
. 2024 Aug;
8(22):5838-5852.
PMID: 39093984
Several attempts have been made to optimize pretransplant risk assessment to improve hematopoietic stem cell transplantation (HSCT) decision-making and to predict post-HSCT outcomes. However, the relevance of pretransplant risk assessment...
3.
Golden O, Gutierrez M, OFlaherty J, Unger K, Doyle B, Keogh T, et al.
Zoonoses Public Health
. 2024 Mar;
71(6):663-672.
PMID: 38544332
Background: Campylobacter is the most common food-borne pathogen in the European Union. In 2018, the crude incidence rate in Ireland was 63.6 per 100,000 population. Chicken is considered an important...
4.
Saccardi R, Putter H, Eikema D, Busto M, McGrath E, Middelkoop B, et al.
Bone Marrow Transplant
. 2023 Mar;
58(6):659-666.
PMID: 36894635
From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT...
5.
Wolf J, Lee J, Pearce R, Wilson M, Snowden J, Orchard K
Br J Haematol
. 2022 Jun;
198(4):e51-e53.
PMID: 35655329
No abstract available.
6.
Day J, Elfeky R, Nicholson B, Goodman R, Pearce R, Fox T, et al.
J Clin Immunol
. 2022 May;
42(6):1230-1243.
PMID: 35579633
Purpose: Allogeneic hematopoietic stem cell transplant (HSCT) remains the treatment of choice for patients with inborn errors of immunity (IEI). There is little published medical outcome data assessing late medical...
7.
Orchard K, Dignan F, Lee J, Pearce R, Desai M, McFarlane E, et al.
Br J Haematol
. 2021 Jan;
192(3):467-473.
PMID: 33474730
No abstract available.
8.
Kelsey P, Pearce R, Perry J, Kirkland K, Paul R, Lambert J, et al.
Bone Marrow Transplant
. 2020 Sep;
56(3):730-732.
PMID: 32994456
No abstract available.
9.
Burney C, Wadhera K, Breslin P, Pearce R, Wells M, Alajangi R, et al.
Biol Blood Marrow Transplant
. 2020 Sep;
26(12):2271-2278.
PMID: 32890747
BiCNU (carmustine), etoposide, Ara-C, melphalan (BEAM) and Campath conditioning was developed to reduce the high transplant-related mortality in patients with lymphoma while delivering intensive antilymphoma immunotherapy, as well as to...
10.
Snowden J, Saccardi R, Orchard K, Ljungman P, Duarte R, Labopin M, et al.
Bone Marrow Transplant
. 2019 Nov;
55(4):838-839.
PMID: 31754251
An amendment to this paper has been published and can be accessed via a link at the top of the paper.